Featured poster 1: Detection of KMT2A-PTDs in healthy donor and myeloid malignant samples using next generation sequencing

• KMT2A (MLL) fusions and KMT2A-PTD (partial tandem duplication) are important biomarkers in myeloid malignancies.
• Acute leukemias harboring KMT2A rearrangements may be susceptible to small molecule inhibitors that target the KMT2A-menin protein complex¹.
• The use of NGS with the Oncomine Myeloid Assay GX v2 on the Ion Torrent Genexus System demonstrated the ability to detect KMT2A fusions in myeloid malignancy samples and KMT2A-PTDs in both healthy donors and myeloid malignancy samples.

Featured poster 2 : A comprehensive genomic profiling of myeloid malignancies demonstrates mutational spectrum of DNA variants, FLT3-ITDs, and gene fusion

• Myeloid malignancies encompass diverse hematopoietic disorders, including AML, MPN, MDS, CML, CMML, JMML.
• The use of NGS with two Oncomine Myeloid Assays demonstrated the ability to detect mutations in 45 DNA genes and >30 fusion driver genes, including >700 fusion isoforms across >8500 clinical research samples.
• Genetic alterations such as FLT3-Internal Tandem Duplications (ITDs), IDH1/2, CEBPA, CALR, and TP53 and rare fusions like ZMYM2-FGFR1/ KAT6A-CREBBP were detected with NGS.